Here's a neat infographic from Cancer Research UK summarizing a new Cell report from UK researchers that describes how conditions build to trigger cancer.…
MolMed has received conditional market approval for Zalmoxis, an ex vivo genetically engineered cell therapy that stops immune rejection of transplanted hematopoietic stem…
Stemedica International, a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer’s disease and dementia, revealed the first…